Back to Search
Start Over
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
- Source :
- American Heart Journal; Mar2021, Vol. 233, p141-148, 8p
- Publication Year :
- 2021
-
Abstract
- We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P < .001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00028703
- Volume :
- 233
- Database :
- Supplemental Index
- Journal :
- American Heart Journal
- Publication Type :
- Academic Journal
- Accession number :
- 148773203
- Full Text :
- https://doi.org/10.1016/j.ahj.2020.12.008